Novartis | NOVN - Sales Revenues



Novartis reported $14.05B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Alcon AG USD 2.58B 130M Jun/2025
Almirall EUR 275M 9.6M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Autolus Therapeutics Ltd 20.9M 18.8M Jun/2025
Bayer EUR 10.74B 3B Jun/2025
Biogen USD 2.6B 170M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Fresenius EUR 5.58B 70M Jun/2025
Fresenius Medical Care EUR 4.79B 90M Jun/2025
Galapagos EUR 70.17M 4.81M Jun/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
GRIFOLS EUR 1.89B 100M Jun/2025
Hikma Pharmaceutical USD 1.59B 18M Dec/2024
J&J USD 23.74B 1.85B Jun/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 4.43B 850M Jun/2025
Merck USD 15.81B 280M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Novartis USD 14.84B 1.28B Jun/2025
Novo Nordisk 76.86B 1.23B Jun/2025
Orion EUR 416.5M 61.9M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Philips EUR 4.34B 241M Jun/2025
Recordati EUR 643.15M 36.81M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
UCB EUR 3.49B 129M Jun/2025